RESUMO
Hemophagocytic lymphohistiocytosis (HLH) is an immune dysregulatory syndrome characterized by severe inflammation and end-organ damage. Due to significant organ dysfunction, patients often require extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). In this report, we describe consideration for adjusting treatment in the context of extracorporeal organ support. We describe agents commonly used and dosing adjustments made in light of extracorporeal organ support. We report six cases that illustrate the feasibility of initiating standard HLH therapies in patients requiring these modalities.
Assuntos
Anti-Inflamatórios/uso terapêutico , Dexametasona/uso terapêutico , Etoposídeo/uso terapêutico , Oxigenação por Membrana Extracorpórea , Linfo-Histiocitose Hemofagocítica/tratamento farmacológico , Pré-Escolar , Terapia de Substituição Renal Contínua , Humanos , Lactente , Recém-Nascido , Unidades de Terapia Intensiva Pediátrica , Estudos RetrospectivosAssuntos
Transplante de Células-Tronco de Sangue do Cordão Umbilical , Síndromes de Imunodeficiência/diagnóstico , Receptores de Interferon/genética , Deleção de Sequência/genética , Análise Mutacional de DNA , Humanos , Síndromes de Imunodeficiência/terapia , Lactente , Masculino , Fosforilação , Fator de Transcrição STAT1/metabolismo , Receptor de Interferon gamaAssuntos
Adenosina Desaminase/deficiência , Anemia Aplástica/tratamento farmacológico , Anemia Aplástica/etiologia , Doenças da Medula Óssea/tratamento farmacológico , Doenças da Medula Óssea/etiologia , Hemoglobinúria Paroxística/tratamento farmacológico , Hemoglobinúria Paroxística/etiologia , Peptídeos e Proteínas de Sinalização Intercelular/deficiência , Fator de Necrose Tumoral alfa/uso terapêutico , Anemia Aplástica/diagnóstico , Biomarcadores , Biópsia , Medula Óssea/patologia , Doenças da Medula Óssea/diagnóstico , Transtornos da Insuficiência da Medula Óssea , Testes Hematológicos , Hemoglobinúria Paroxística/diagnóstico , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Imunodeficiência Combinada Severa/diagnóstico , Imunodeficiência Combinada Severa/etiologia , Avaliação de Sintomas , Resultado do TratamentoRESUMO
As survival rates in allogeneic hematopoietic stem cell transplantation (HSCT) continue to improve, attention to long-term complications, including cardiovascular disease, becomes a major concern. Cardiovascular disease and dyslipidemia are a common, yet often overlooked occurrence post-HSCT that results in significant morbidity and mortality. Also, increasing evidence shows that several anti-hyperlipidemia medications, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in particular, may have a role in modulating graft-versus-host disease (GVHD). However, factors such as drug-drug interactions, adverse effect profiles, and the relative efficacy in lowering cholesterol and triglyceride levels must be taken into account when choosing safe and effective lipid-lowering therapy in this setting. This review seeks to provide guidance to the clinician in the management of dyslipidemia in the allogeneic HSCT population, taking into account the recently published American College of Cardiology/American Heart Association guidelines on hyperlipidemia management, special considerations in this challenging population, and the evidence for each agent's potential role in modulating GVHD.
Assuntos
Dislipidemias/tratamento farmacológico , Doença Enxerto-Hospedeiro/tratamento farmacológico , Transplante de Células-Tronco Hematopoéticas , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Aloenxertos , Interações Medicamentosas , Dislipidemias/sangue , Doença Enxerto-Hospedeiro/sangue , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/efeitos adversos , Guias de Prática Clínica como AssuntoRESUMO
Chemotherapy-induced nausea and vomiting (CINV) involves multiple neurotransmitter and receptor systems; thus, its optimal treatment is likely to require a combination of therapies targeting multiple systems. Antiemetic regimens have evolved from use of dopamine antagonists alone to combination regimens such as a corticosteroid plus an antagonist of the serotonin (5-hydroxytryptamine) type 3 receptor or this combination with a neurokinin-1 receptor antagonist. The net result is that antiemetic efficacy has markedly increased with the addition of each new class of agent to treatment regimens. Further research is needed to determine optimal uses of available classes and agents for managing CINV, to elucidate the roles of additional neurotransmitters and receptors in both nausea and vomiting, and to develop new antiemetic agents.